DDInter580 DDInter1376
Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Dofetilide {u} (Compound) resembles {v} (Compound) Dronedarone
Dofetilide {u} (Compound) resembles {v} (Compound) Rosiglitazone
Dofetilide {u} (Compound) binds {v} (Gene) KCNH2
Dofetilide {u} (Compound) upregulates {v} (Gene) CASP7
Dofetilide {u} (Compound) downregulates {v} (Gene) CDCA4
Dofetilide {u} (Compound) causes {v} (Side Effect) Dyspnoea
Dofetilide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Dofetilide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Troglitazone
Dofetilide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Dofetilide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Octreotide
Dofetilide (Compound) resembles Dronedarone (Compound)
Dofetilide (Compound) resembles Rosiglitazone (Compound)
Dofetilide (Compound) binds KCNH2 (Gene)
Dofetilide (Compound) upregulates CASP7 (Gene)
Dofetilide (Compound) downregulates CDCA4 (Gene)
Dofetilide (Compound) causes Dyspnoea (Side Effect)
Dofetilide may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Dofetilide may cause a minor interaction that can limit clinical effects when taken with Troglitazone
Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol
Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Octreotide